TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers
Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
The primary to assess the safety and tolerability of TA-CIN and anti-PD-1 therapy in patients
with recurrent HPV16-associated cancers and to assess the feasibility of IT injection of
TA-CIN in patients with recurrent HPV16-associated cancers undergoing treatment with
anti-PD-1 therapy.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins